KRAS and cancer: Covalent KRAS inhibitors have demonstrated promise in preclinical models, but they are only effective against a specific KRAS‐mutant allele and additional agents are needed to optimize the anti‐cancer efficacy (Ostrem et al, 2013; Janes et al, 2018; Molina‐Arcas et al, 2019).